Eileen M O'Reilly MD discusses the promising results of the RASolute 302 Study presented at ASCO 2026, highlighting the drug Daraxonrasib's impact on survival rates in pancreatic cancer patients.
Standing ovation at ASCO for RASolute 302 Study
People in this episode
Guest: Eileen M O'Reilly MD
Topics covered
oncology
pancreatic cancer
drug development
clinical trials
ASCO 2026
RAS targeting
Keywords
Daraxonrasib
RAS G12
pancreatic cancer
ASCO 2026
RASolute 302 Study
survival rates
clinical trial results
Mentioned in this episode
Organizations: ASCO
Products: Daraxonrasib
Places: Pancreas Cancer
More episodes of Audio Journal of Oncology Podcast